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1. Introduction 
The introduction of the highly active antiretroviral therapy (HAART) for the treatment of 
HIV-1-infection has dramatically improved the quality of life and the survival of HIV-
infected patients. HAART can effectively suppress virus replication and thereby helps to 
preserve immune functions. However, as HIV-1 persists in latently infected reservoirs (Finzi 
et al., 1997), complete eradication of the virus by antiretroviral drugs has never been 
achieved and life-long treatment is required. Moreover, emerging viral resistance and drug 
toxicity restrict long-term therapeutic efficacy (Brinkman et al., 1999; Vigouroux et al., 1999). 
As a consequence, HAART has not had a major impact on the global prevalence of HIV-
infection and there is no vaccine in sight that could prevent further virus spread. 
In addition to HAART and vaccines, gene therapy approaches for HIV-1 infection have been 
under investigation for more than two decades. Gene therapy could theoretically overcome 
the limitations of standard antiretroviral drug therapy and facilitate sustained suppression 
of virus replication after only few treatment cycles. Moreover, the choice of adequate genes 
or combinations of genes and expression systems could greatly reduce toxicity and prevent 
the generation of resistant virus strains. Although gene therapy is an expensive and 
technically challenging therapy today, future developments could simplify the procedures 
involved and bring down costs. Two basic gene therapeutic strategies for immune 
reconstitution of AIDS patients have been developed and the safety and efficacy of different 
approaches have been examined in preclinical and clinical studies. The first strategy aims to 
specifically kill HIV-infected cells by enhancing the antiviral host immune responses. The 
second approach, termed ‘intracellular immunization’, is based on the expression of 
antiviral genes that prevent HIV-1 replication in its target cells. Furthermore, therapeutic or 
prophylactic vaccination strategies that aim to enhance anti-HIV immunity and use DNA or 
viral vectors to express the viral antigens can formally be classified as gene therapy 
approaches. However, such vaccination strategies are not in the scope of this review. 
2. Enhancing HIV-specific immunity: Adoptive transfer of CD8
+
 T cells 
The striking ability of HIV-1 to evade control by the host immune system is a fundamental 
problem in AIDS pathogenesis. Although most patients develop natural anti-HIV immune 
responses, the virus does not possess the immunogenicity to mount long-lasting responses 
strong enough to entirely suppress replication and to allow complete virus eradication from 
the body. In fact, most affected individuals initially develop immunodominant CD8+ T cell 
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(cytotoxic T lymphocyte, CTL) responses during the acute phase of HIV-1 infection, 
resulting in transient virus control and a decrease in plasma viremia (Borrow et al., 1994). 
The importance of CTLs was further confirmed in experiments with SIV-infected non-
human primates, where acute infection could not be controlled in animals depleted of CD8+ 
T lymphocytes (Schmitz et al., 1999). There is a strong negative correlation between 
emergence of virus-specific CTLs and the viral set point, as patients with strong early CTL 
responses show significantly lower viral set points and a slower disease progression (Streeck 
et al., 2009). However, later, during the chronic phase of HIV-1 infection generation of CD8+ 
T cell responses seems to be impaired and dysfunctional CTLs fail to control virus 
replication in most patients. In contrast, long-term non-progressors – individuals which are 
HIV-1 seropositive, but do not progress to AIDS – retain high levels of virus-specific T cells, 
indicating that functional CTL responses are crucial for efficient virus control also in chronic 
infection (Rinaldo et al., 1995). 
One reason for the failure of HIV-specific immunity during the chronic stage of infection 
may be the high variability of the virus resulting from a high replication rate and error-
prone reverse transcription (Phillips et al., 1991). Moreover, HIV-1 attacks the immune 
system itself, the CD4+ helper T cell being its major target cell. This results in the preferential 
infection and a massive loss of HIV-specific CD4+ T cells already early upon infection, as the 
virus-specific helper cells migrate to the site of infection where they become activated 
thereby becoming more susceptible to HIV-1 infection (Demoustier et al., 2002; Douek et al., 
2002). Yet, virus-specific CD4+ T cells are urgently needed to help generating strong, durable 
immune responses and their absence impairs CTL activation and maturation (Kemball et al., 
2007; Matloubian et al., 1994). In addition, progressive exhaustion of virus-specific CD8+ T 
cells is a hallmark of the chronic immune activation during ongoing HIV-1 infection. Here, 
the constant antigen persistence prevents contraction of the effector T cell pool and 
development of long-lived memory cells. Instead, a stepwise exhaustion characterized by 
metabolic and transcriptional changes, reduced cytokine and chemokine secretion, loss of 
proliferation capacity and cytolytic activity is observed, resulting in impaired CTL effector 
functions and finally apoptosis (Shankar et al., 2000; Trimble & Lieberman, 1998). 
Boosting of the natural CTL responses against HIV-1 by cell and gene therapeutic strategies 
may help to overcome these problems. For this purpose two different strategies have been 
developed; the adoptive transfer of autologous antigen-specific T cells after ex vivo selection 
and expansion, and the infusion of genetically armed CD8+ T cells expressing HIV-specific T 
cell receptors (TCRs). A therapy combining these approaches with the protection of CD4+ T 
cells to preserve important T-helper cell functions could potentially impact infection 
dynamics and ultimately facilitate clearance of the virus. 
The adoptive transfer of autologous, antigen-specific CD8+ T cell clones has been used 
successfully to treat persistent viral infections and cancer. The allogeneic organ 
transplantation from cytomegalovirus or Epstein-Barr virus seropositive donors, for 
instance, is associated with risks for the recipient, if untreated. Co-transplantation of virus-
antigen-specific T cells isolated from the donor and expanded in vitro, enhanced T cell 
immunity to the viruses and prevented adverse effects in the immunosuppressed recipients 
(Heslop et al., 1996; Walter et al., 1995). For HIV-1, however, the transfer of ex vivo expanded 
virus-specific CTLs had only limited success in patients so far. In a study reported by Brodie 
et al. autologous Gag-specific CTLs were isolated and reinfused into HIV-positive 
individuals (Brodie et al., 1999). The CTLs engrafted in the patients and were found to 
migrate to the lymph nodes, which are the major sites of HIV-1 replication (Brodie et al., 
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2000; Hufert et al., 1997). However, although the CTLs were capable of lysing HIV-1 infected 
cells in vivo, only a transient effect on virus replication was observed (Brodie et al., 1999; 
Brodie et al., 2000). A major problem of this therapeutic concept is that the CTLs isolated 
from patients with advanced disease are often exhausted and terminally differentiated and 
lack full effector functions. As in vitro expansion of these cells is accompanied with a further 
loss of function, the transferred cell numbers may be insufficient to induce long-term effects. 
Methods that allow generation of large numbers of fully functional CTLs therefore would be 
required to facilitate success of this promising therapy approach. 
An alternative to the isolation and expansion of existing antigen-specific T cells from a 
patient, is the genetic modification of cells resulting in the expression of recombinant HIV-
specific receptors. The cell types used for this genetic ‘redirection’ can be peripheral blood T 
cells, but also hematopoietic stem cells (HSC), which can afterwards differentiate into 
immune cells targeting HIV-1. As the isolation and manipulation of T cells is currently 
easier to perform compared to stem-cell modification, all studies that have been conducted 
so far used peripheral blood T cells. The receptors used to redirect the immune cells to target 
HIV-1 can either be natural T cell receptors or artificial chimeric antigen receptors (CARs). 
For the natural TCRs, CTL clones with high avidity TCRs specific for the target antigens are 
selected in vitro. The alpha and beta chains of these TCRs are then cloned and used to 
transduce patient T cells. This approach has been used successfully in the clinic to treat 
patients with melanoma, where in some cases tumor regression has been observed (Morgan 
et al., 2006). The isolation and cloning of high-avidity HIV-specific TCRs is also feasible. 
Joseph and colleagues constructed a lentiviral vector expressing a TCR specific for the HIV-1 
Gag epitope SL9. Transduction of human primary T cells led to the conversion of peripheral 
blood CD8+ T cells into HIV-specific CTLs (Joseph et al., 2008). These CTLs exerted anti-HIV 
activity in vitro and in vivo in a humanized mouse model. In a similar study, an SL9-specific 
TCR with enhanced affinity was shown to efficiently mediate control of HIV-1 in vitro 
(Varela-Rohena et al., 2008). Currently this approach is evaluated in a phase I clinical trial 
(www.ClinicalTrials.gov; identifier: NCT00991224). The use of natural TCRs to generate 
virus-specific CTLs is limited by the major histocompatibility complex (MHC)-restriction of 
the TCR. TCRs recognize peptides only if they are presented on a specific type of MHC. 
Therefore, T cells expressing a given TCR can only be used for treatment of MHC-matched 
patients. The clinical trial described above, for instance, can only include patients with the 
HLA-type A*02. For a broader application of this therapy concept a set of TCRs would be 
required that allows treatment of patients with various haplotypes. Besides, in gene 
modified CTLs, the genetically transferred TCR can mispair with the endogenous TCR, 
which may affect its function and lead to autoimmunity. Another drawback of the approach 
is the downregulation of MHC molecules in HIV-infected cells, which impedes the 
presentation of viral peptides and recognition by the CTLs (Sommermeyer et al., 2006). 
CARs are chimeric antigen receptors composed of an extracellular antigen binding motive 
connected to an intracellular signal transduction domain via a flexible linker and a 
transmembrane domain. The antigen binding motive usually is an antigen-specific single-
chain variable fragment derived from a monoclonal antibody, while the signal transduction 
part comes from the CD3 ζ-chain. CARs trigger an MHC-independent antigen recognition 
(Eshhar et al., 2001). Two CARs with HIV-1 specificity have been developed by Roberts and 
colleagues (Roberts et al., 1994). The antigen-binding part consists either of the gp120 
binding domain from human CD4 or an antibody against gp41. T cells transduced with 
either of the receptors specifically recognized and killed HIV-infected cells in vitro. The 
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receptor containing CD4 has been tested in three clinical trials. In these studies local effects 
on virus replication were observed, but unfortunately there was no overall change in viral 
load (Deeks et al., 2002; Mitsuyasu et al., 2000; Walker et al., 2000). 
3. Intracellular immunization: Protection of CD4
+
 T cells 
The second gene therapeutic strategy for HIV-1 infection was termed ‘intracellular 
immunization’ (Baltimore, 1988) and involves the expression of an antiviral gene in cells 
susceptible to HIV-1 infection. The target cells for intracellular immunization strategies 
therefore are mainly peripheral T cells or hematopoietic stem cells. The gene product can 
either be a protein or an RNA that inhibits HIV-1 replication by interfering with crucial 
steps of the viral life cycle or by targeting a cellular factor required for virus replication. 
Efficient genetic protection of the HIV-1 target cell population, i.e. mainly CD4+ T-helper 
cells, will deprive the virus of the possibility to produce progeny and is therefore expected 
to result in a drop of viral load and a regeneration of T cell counts. An additional antiviral 
effect can be achieved, if sufficient T-helper cell clones specific for HIV-1 antigens are 
protected against viral infection. These gene-protected CD4+ T cells could support the 
immunologic control of viral replication, without risking infection facilitated by HIV-1 
antigen activation. As mentioned above, previous studies have shown that HIV-specific T-
helper cell clones, which are crucial for an effective immune control of HIV-1 replication, are 
preferentially infected by HIV and lost during the course of the disease (Douek et al., 2002). 
3.1 Antiviral proteins 
Various types of anti-HIV proteins have been developed over the past years. Dominant-
negative forms of both, viral proteins and cellular proteins required for virus replication 
have been described. These dominant-negative mutant proteins antagonize the activity of 
their corresponding wild-type proteins and thus prevent viral replication. A transdominant 
form of the HIV-1 Rev protein, RevM10, has been extensively studied in vitro and in vivo. 
RevM10 prevents the export of genomic viral RNA from the nucleus and as a result inhibits 
production of progeny virus (Malim et al., 1989). In clinical trials genetic modification of 
CD4+ T cells and CD34+ hematopoietic stem cells with RevM10 has been shown to be safe 
and provide some selective survival advantage. However, no sustained absolute 
accumulation of gene-modified cells and accordingly no antiviral effect was observed 
(Morgan et al., 2005; Podsakoff et al., 2005; Ranga et al., 1998; Woffendin et al., 1996). 
Furthermore, transdominant mutants of HIV-1 Tat that prevent Tat transactiviation have 
been developed (Fraisier et al., 1998; Pearson et al., 1990), but were never tested in clinical 
trials. The same is true for transdominant forms of the HIV-1 proteins Gag (Trono et al., 
1989) and Vif (Morgan et al., 1990; Vallanti et al., 2005). 
Cellular proteins required for virus replication have also been targeted by dominant-
negative mutants. Membrane expression of chemokine receptor 5 (CCR5), which acts as a 
co-receptor for HIV-1, has been blocked by transdominant negative CCR5 variants upon 
retroviral expression in human T cells (Luis Abad et al., 2003). Even though inhibition of 
virus replication was observed in the gene-modified cells, this concept was not pursued 
further. A truncated soluble form of the cell surface receptor CD4 (sCD4) has been described 
to protect T cells from entry of laboratory-adapted strains of HIV-1, however, inhibition was 
less efficient for primary virus isolates (Daar & Ho, 1991; Morgan et al., 1994; Morgan et al., 
1990). In a clinical phase I study recombinant soluble CD4 was administered by continuous 
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intravenous infusion to paediatric AIDS patients. Although the therapy was well tolerated, 
evidence of in vivo antiviral activity was not observed and consequently, sCD4 has never 
been investigated in gene therapy clinical trials (Husson et al., 1992). 
Nevertheless, gene therapeutic strategies targeting early steps in the viral life cycle are 
expected to be the most promising therapeutics for HIV/AIDS, as discussed below. Protein-
based inhibitors targeting the virus entry process are thought to be especially powerful tools 
as they can prevent infection of the cell. Our group has previously developed a membrane-
anchored gp41-derived HIV-1 fusion inhibitor, maC46. This protein is expressed on the 
surface of T cells after transduction with retroviral or lentiviral vectors (Egelhofer et al., 
2004; Hermann et al., 2009b; Perez et al., 2005). The protein binds to the HIV-1 gp41 heptad 
repeat 1 region thereby interfering with six-helix bundle formation during the viral and 
cellular membrane fusion process. MaC46 expressing T cells are almost completely 
protected from HIV-1 entry and have a strong selective survival advantage compared to 
unmodified cells in vitro and in mouse models of HIV-1 infection (Egelhofer et al., 2004; 
Hermann et al., 2009a; Kimpel et al., 2010). Likewise, maC46 has been shown to be one of 
the most potent anti-HIV gene products currently available (Kimpel et al., 2010). However, 
in a clinical trial with 10 HIV-1-infected patients with advanced disease and HAART failure, 
infusion of autologous CD4+ T cells genetically modified to express maC46 did not achieve 
sustained success. Although a significant rise in overall CD4+ T cell counts was observed in 
this study, the gene-protected cells did not accumulate over time and consequently, viral 
loads were not affected (van Lunzen et al., 2007). Recently, we described a secreted version 
of the fusion inhibitory C46 molecule. This ‘in vivo secreted antiviral entry inhibitor’ (iSAVE) 
showed promising anti-HIV activity in vitro and has the potential to confer an overall 
antiviral effect in vivo despite low levels of gene marking (Egerer et al., 2011). 
A different protein-based approach for HIV-1 gene therapy uses antibodies that bind and 
inactivate proteins and enzymes required for virus replication. Antibodies can be expressed 
within gene-modified cells as single-chain fragments (scFv), so-called intrabodies, or they 
can be secreted into the supernatant as neutralizing antibodies. Various intrabodies against 
HIV-1 proteins including Tat, Vif, Reverse Transcriptase and Integrase have been shown to 
inhibit virus replication in gene-modified cells in vitro (Goncalves et al., 2002; Kitamura et 
al., 1999; Levy-Mintz et al., 1996; Mhashilkar et al., 1995; Shaheen et al., 1996). Moreover, 
intrabodies against the viral co-receptors CXCR4 and CCR5 have been designed that retain 
these proteins in the ER (BouHamdan et al., 2001; Cordelier et al., 2004; Swan et al., 2006). 
Although these approaches efficiently inhibited HIV-1 replication in cell culture systems, 
intrabody techniques have not been further evaluated in vivo. The secreted version of the 
broadly neutralizing anti-gp41 monoclonal antibody 2F5 has been analyzed in a humanized 
mouse model of HIV-1 infection (Sanhadji et al., 2000). In this study, gene-modified cell lines 
expressing the antibody were implanted as neo-organs into immunodeficient mice 
repopulated with human CD4+ T cells. The neo-organs engrafted in the peritoneum and 
permitted continuous secretion of the antibody. Upon infection of the mice with HIV-1, viral 
loads were greatly reduced compared to control animals. However, due to safety problems, 
the implantation of neo-organs is not an option for treatment of patients. Recently, Joseph 
and colleagues reported the secretion of therapeutic concentrations of the broadly 
neutralizing anti-gp120 antibody 2G12 in humanized mice. Here, immunodeficient mice 
were transplanted with human hematopoietic stem cells that had previously been modified 
with a lentiviral vector encoding 2G12. The transduced stem cells differentiated into human 
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progeny cells that secreted the functional antibody into the serum. This genetic 
immunization clearly reduced viral burden upon HIV-1 infection (Joseph et al., 2010). 
Another strategy described by Sarkar et al. involves the expression of a modified version of 
the Cre recombinase (termed Tre) in HIV-1 infected cells. This recombinase has been 
engineered in a directed evolution approach to recombine a sequence present in the HIV-1 
LTRs resulting in site-specific excision of the integrated provirus from an HIV-1 infected 
host cell genome (Sarkar et al., 2007). Even though proof-of-concept was provided in vitro, 
this approach is far from clinical application as the Tre recombinase is specific for one 
exclusive LTR sequence and does not recognize the LTRs of other virus strains. 
Finally, zinc finger nucleases (ZFNs) are a novel tool in protein-based HIV-1 gene therapy. 
ZFNs are artificial fusion proteins composed of a DNA-binding and a DNA-cleavage 
domain. They can be engineered to bind any desired genome sequence and induce double-
strand breaks in the targeted DNA. Repair of the damaged DNA is associated with the 
introduction of high-frequency deletions and insertions at the site of cleavage. Individuals 
with a naturally occurring 32 bp deletion mutant of the CCR5 receptor (CCR5∆32) are 
perfectly healthy, but resistant to infection with R5-tropic strains of HIV-1 (Huang et al., 
1996; Samson et al., 1996). Consequently, disruption of the CCR5 locus using ZFNs is not 
expected to alter immune functions, making it an ideal target for ZFN-based gene therapy. 
CCR5-specific ZFNs have been studied in vitro and in animal models and were shown to 
render the treated cells resistant to HIV-1 infection (Holt et al., 2010; Perez et al., 2008). 
Currently three clinical trials are recruiting patients to test this promising approach in vivo 
(www.ClinicalTrials.gov; identifier: NCT01044654, NCT01252641 and NCT00842634).  
3.2 Antiviral RNAs 
Antiviral RNAs for intracellular immunization can be grouped into four major categories: 
RNA interference (RNAi), ribozymes, anti-sense RNAs and RNA decoys. Several RNAi-
based gene therapy regimens for treatment of HIV-1 infection have proven to be effective in 
blocking viral replication by selective degradation of either viral RNAs or mRNAs of host 
factors that are essential for HIV-1 replication. Basically all HIV-1 RNAs have been 
successfully downregulated by RNAi in vitro (Chang et al., 2005; Coburn & Cullen, 2002; 
Jacque et al., 2002; N. S. Lee et al., 2002; Novina et al., 2002). However, systemic delivery of 
siRNAs to the relevant cell types in vivo is difficult. Kumar and colleagues administered 
antiviral siRNAs conjugated to a T cell-specific single-chain antibody that undergoes 
internalization upon binding to T cell surface receptors to humanized mice. This approach 
allowed targeted delivery of the siRNAs to T cells, which resulted in effective virus 
inhibition and preserved CD4+ T cell numbers (Kumar et al., 2008). An alternative to the 
regular injection of exogenous siRNAs is the expression of shRNAs directly in the HIV-1 
target cells, but achieving stable transgene expression in the gene-modified cells is a 
challenge. Yet, constant endogenous expression would be required to obtain efficient 
suppression of HIV-1 replication and prevent viral escape mutants. At the same time, 
expression levels have to be tightly regulated in order to avoid cellular toxicity, as saturation 
of the cellular small RNA-processing pathway due to overexpression of shRNAs can lead to 
downregulation of cellular microRNAs (miRNAs) and cause severe toxicity (Grimm et al., 
2006). Insertion of shRNAs into a natural miRNA backbone has been shown to reduce such 
toxic effects (McBride et al., 2008). 
The high mutation rate of HIV-1 is an additional challenge in developing RNAi-based 
therapeutics, as a single point mutation within the targeted HIV-1 RNA sequence can 
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abolish function of small RNAs and escape mutants emerge rapidly (Boden et al., 2003; Das 
et al., 2004; Sabariegos et al., 2006). This problem can be partly overcome by using a 
combination of small RNAs targeting several conserved regions of the viral genome and 
ideally expressed from a single therapeutic vector (ter Brake et al., 2006). Alternatively, 
cellular genes required for virus replication can be targeted, including CD4, CXCR4, CCR5, 
nuclear factor κB, or LEDGF/p75, which all have been shown to be susceptible to RNAi 
silencing, thereby blocking viral entry or replication (Anderson & Akkina, 2005; Cordelier et 
al., 2003; Novina et al., 2002; Surabhi & Gaynor, 2002; Vandekerckhove et al., 2006). The 
CCR5 receptor is a particularly promising target, as disruption of the CCR5 gene does not 
alter immune functions (Huang et al., 1996; Samson et al., 1996). A highly potent and non-
cytotoxic siRNA directed against CCR5 has been developed by the group of Irvin Chen. 
Stable long-term expression of the siRNA and silencing of the CCR5 gene was observed 
after transplantation of gene-modified CD34+ hematopoietic progenitor cells in non-human 
primates. Gene-modified cells isolated from the animals were resistant to simian 
immunodeficiency virus infection ex vivo (An et al., 2007; Liang et al., 2010). The only RNAi 
approach that has been examined in patients so far is a tat/rev specific short hairpin RNA, 
which was tested in combination with a ribozyme targeting CCR5 and a TAR decoy in four 
patients receiving CD34+ hematopoietic progenitor cell transplantation due to AIDS-related 
lymphoma. In this recently reported clinical trial, stable, but low-level expression of the 
antiviral RNAs from gene-modified cells was observed for up to 24 months; however, there 
were no major effects on viral load (DiGiusto et al., 2010). 
Ribozymes are anti-sense RNA molecules with enzymatic activity that have been designed 
to target and site-specifically cleave essential viral RNAs or cellular mRNAs leading to gene 
silencing. Many ribozyme-based strategies for treatment of HIV-1 infection have been 
developed and show promising antiviral activity in vitro (Hotchkiss et al., 2004; Sarver et al., 
1990; Zhou et al., 1994). Three ribozymes directed against HIV-1 tat/vrp (Amado et al., 2004; 
Macpherson et al., 2005; Mitsuyasu et al., 2009), HIV-1 rev/tat (Michienzi et al., 2003) and 
the viral U5 leader region (Wong-Staal et al., 1998) have already been tested in separate 
clinical trials. The gene transfer was proven to be safe in all studies, but none showed 
significant antiviral efficacy. As mentioned above, a CCR5-specific ribozyme has recently 
been analyzed in the clinic in combination with two other types of anti-HIV RNAs, but did 
not have a major influence on HIV-1 replication (DiGiusto et al., 2010). 
Antisense RNAs are short or long single-stranded RNA molecules binding to 
complementary HIV-1 mRNAs resulting in the formation of non-functional duplexes. 
Antisense molecules directed against the HIV-1 trans-activation response element (TAR) 
and the viral envelope RNA have been developed (Humeau et al., 2004; Lu et al., 2004; 
Vickers et al., 1991). The conditionally replicating lentiviral vector VRX496TM encodes a long 
antisense gene against the HIV-1 envelope. In clinical trials patients received autologous 
CD4+ T cells transduced with VRX496TM. A stabilization of viral load and slightly increased 
CD4+ T cell counts were observed, the significance of these results, however, remains 
unclear (Levine et al., 2006). 
In contrast to the antiviral RNA molecules described above, RNA decoys do not attack the 
HIV-1 RNA. Instead, these small RNA fragments, which are derived from cis-acting 
elements in the viral genome, competitively bind and sequester viral proteins, thereby 
interfering with HIV-1 replication. Anti-HIV decoys are mainly based on the HIV-1 
regulatory sequences TAR and Rev-responsive-element (RRE), which are bound by the two 
HIV-1 regulatory proteins Tat and Rev, respectively. The TAR element is a sequence 
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contained in the 5’ region of all HIV-1 mRNAs, which forms a stable stem-loop structure 
(Baudin et al., 1993; Muesing et al., 1987). Binding of the HIV-1 Tat (trans-activator) protein 
to the TAR element mediates increased viral gene expression (Keen et al., 1996); moreover, 
the TAR region is required for initiation of reverse transcription (Harrich et al., 1996). 
Disruption of the Tat/TAR interaction by TAR decoy RNA was shown to effectively prevent 
HIV-1 replication in vitro (Sullenger et al., 1990, 1991). A combination of three antiviral 
RNAs including a TAR decoy was successfully tested in humanized mouse models of HIV-1 
infection (Anderson et al., 2007) and, as mentioned above, was shown to be safe in a clinical 
trial, although only minor effects on HIV-1 infection could be observed (DiGiusto et al., 
2010). Interaction of the viral Rev protein with the RRE is critically required for transport of 
the unspliced genomic viral mRNA to the cytoplasm (Olsen et al., 1990). RRE decoys 
provide strong inhibition of HIV-1 replication by blocking the nuclear export of genomic 
HIV-1 RNA (T. C. Lee et al., 1992; Michienzi et al., 2006). Genetic modification of CD34+ 
hematopoietic stem cells by retroviral transfer of an RRE decoy gene followed by infusion of 
the gene-modified cells, was shown to be safe in a clinical trial with paediatric AIDS 
patients. However, transduction and engraftment levels were very low and no antiviral 
effect was observed (Kohn et al., 1999). 
3.3 The mode of action: Classification of antiviral genes 
The impact of gene-modified cells on systemic HIV-1 kinetics depends critically on the stage 
of the viral replication cycle at which the inhibition occurs. The antiviral genes can 
accordingly be grouped into three classes, depending on their effect on the viral life cycle 
(von Laer et al., 2006). Class I genes inhibit the first steps of the replication cycle prior to 
integration of the proviral DNA into the host cell genome and thus prevent infection of the 
cell. Hence, class I includes genes encoding entry inhibitors, as well as inhibitors of reverse 
transcription and integration. Class II genes have no effect on early steps of the viral 
replication cycle, but prevent the expression of viral RNA or proteins. Thus, they inhibit the 
production of infectious virus progeny and the viral cytopathic effect, however, integration 
of the proviral genome into the host cell chromosomes is not hindered. Cells expressing a 
class II gene and infected with HIV-1 resemble latently infected cells and according to 
computer simulations accumulate with time, counteracting the antiviral effect (von Laer et 
al., 2006). Furthermore, reverse transcription, which can give rise to resistant virus variants, 
is not inhibited by class II genes. Class III genes interfere with late steps in the viral life cycle 
such as virion assembly and budding. Consequently, they neither protect the infected cell 
from recognition by the immune system, as viral protein production is not inhibited, nor 
from the viral cytopathic effect. Therefore, class III genes alone are not expected to have an 
overall antiviral effect unless high percentages of cells are genetically modified. 
Mathematical modelling predicts that only genes inhibiting early steps in the viral 
replication cycle provide a selective advantage strong enough to allow for the selection and 
accumulation of the gene modified cells (Lund et al., 1997; von Laer et al., 2006). 
Consequently, class I genes are the most promising candidates for successful intracellular 
immunization strategies. The group of Warner Greene recently found that in ex vivo cultures 
of human tonsils infected with HIV-1 the vast majority of CD4+ T cells died due to non-
productive abortive infection. In these non-permissive cells DNA reverse transcription 
intermediates elicited proapoptotic responses resulting in release of proinflammatory 
cytokines and caspase-mediated cell death (Doitsh et al., 2010). Inhibition of HIV-1 entry or 
early steps of reverse transcription could protect the cells from these fatal effects, indicating 
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that very early inhibitors are even more favorable, as they can prevent the massive 
“bystander” killing observed in HIV-1 infection. However, combination of several antiviral 
genes, targeting different steps in the viral life cycle might synergize most efficiently and 
could be the only way to achieve sustained suppression of HIV-1 replication. 
3.4 Selective survival advantage and bystander effect 
The major drawback of intracellular immunization approaches is the huge number of HIV-1 
target cells in the human body (> 1011) that cannot be genetically modified with the available 
technologies. The frequencies of gene-modified CD4+ T cells achieved in vivo, whether by T 
cell or stem cell targeting, have been disappointingly low, in the range of 0,01% to 1%, or 
less (Amado et al., 2004; Levine et al., 2006; Macpherson et al., 2005; Morgan et al., 2005; van 
Lunzen et al., 2007). A significant impact of these few genetically HIV-resistant cells is 
neither expected on overall HIV-1 infection dynamics nor on immune reconstitution. 
However, if the gene-protected cells are able to proliferate and preferentially survive 
compared with unmodified cells, they could accumulate with time and progressively 
repopulate the immune system (Lund et al., 1997; von Laer et al., 2006). A number of gene 
products that have been developed could theoretically mediate such a selective survival 
advantage of the transduced cells as they have been shown to efficiently suppress virus 
replication and protect the cells from the viral cytopathic effect in vitro. However, selective 
accumulation of gene-protected cells has never been observed in clinical trials so far. In a 
comparative study, we recently evaluated three intracellular immunization strategies that 
had previously been used in the clinic, with respect to antiviral activity and survival 
advantage (Kimpel et al., 2010): (1) the viral entry inhibitor maC46 (class I gene); (2) an 
HIV-1 tat/rev-specific small hairpin (sh) RNA (class II gene); and (3) an RNA antisense gene 
specific for the HIV-1 envelope (class II gene). We found robust inhibition of HIV-1 
replication with the fusion inhibitor maC46 and the antisense envelope inhibitor. 
Interestingly, and importantly, a survival advantage was merely demonstrated for cells 
expressing the maC46 fusion inhibitor both in vitro and in vivo in a humanized 
xenotransplant mouse model (Kimpel et al., 2010). This finding confirms in silico predictions 
stating that only class I genes can confer a sufficient selective advantage to allow preferential 
survival and accumulation of gene-protected, non-infected cells in vivo (von Laer et al., 
2006). However, even this highly active fusion inhibitor failed to show a clear accumulation 
of gene-protected cells to therapeutic levels in a previous clinical trial in 10 AIDS patients 
(van Lunzen et al., 2007). These data show that efficient engraftment and proliferation of the 
gene-protected cells remain a major challenge in gene therapy for HIV-1 infection. 
Yet, such a strong selection and accumulation may not be required for a secreted antiviral 
gene product. Secreted antiviral proteins or peptides are expected to produce a bystander 
effect on unmodified neighboring cells, thereby suppressing virus replication and protecting 
the overall T cell pool even at low levels of gene modification. Such a bystander effect can 
only be conferred by antiviral proteins, but not by RNAs, as secretion is limited to proteins 
and peptides. However, the number of reports on secreted antiviral proteins in HIV-1 gene 
therapy is still very limited. Examples are neutralizing antibodies (Sanhadji et al., 2000), 
truncated soluble CD4 (Morgan et al., 1994; Morgan et al., 1990) and interferon β (Gay et al., 
2004). We have recently reported the generation of an in vivo secreted antiviral entry 
inhibitor (iSAVE), which exerted a strong bystander effect in cell culture (Egerer et al., 2011). 
Lymphatic tissue is the major site of HIV-1 replication and thus T or B cells could be an ideal 
target cell for gene therapy approaches based on secreted gene products. Secretion of 
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antiviral proteins directly in the lymphoid tissues is likely to lead to high and stable local 
peptide concentrations and to substantially suppress virus replication. On the other hand, 
secreted antiviral gene products no longer depend on expression in HIV-1 target cells, but 
instead several other cell types could serve as producer cells in the body. This facilitates the 
development of direct in vivo gene transfer approaches (e.g. by the use of AAV-vectors), 
making gene therapy less complex and practicable also for treatment of patients in the 
developing world. Furthermore, such strategies have the potential for application as a gene 
transfer vaccine in a prophylactic setting. In this regard, a secreted antiviral gene product 
could for instance be used as a genetic topical microbicide that aims at the prevention of 
HIV-1 mucosal transmission. High-level secretion of the antiviral molecules from gene-
modified target cells in the vagina or rectum has the potential to confer local sterilizing 
immunity, thus preventing HIV-1 genital transmission. 
3.5 Immunogenicity of the antiviral gene product 
Gene therapeutic strategies based on the expression of antiviral proteins are limited by the 
potential immunogenicity of the antiviral gene product, which can severely impair survival 
of the transduced cells. Antiviral RNAs have an advantage here, as they generally lack 
immunogenicity. Also, natural or only slightly altered variants of human proteins are not 
expected to mount significant immune responses. However, many antiviral proteins are 
non-self and bear the risk of eliciting a cellular immune response. Thus, to prevent selective 
deletion of the gene-modified cells by transgene-specific CTLs, it is necessary to minimize or 
eliminate immunogenicity of the antiviral gene product. The fusion of a Glycine-Alanine 
repeat derived from the Epstein-Barr virus nuclear antigen 1 (EBNA-1) to immunogenic 
proteins, such as transdominant HIV-1 Gag, has been shown to significantly reduce 
immunogenicity and prolong survival of transduced cells in vivo (Hammer et al., 2008). The 
Glycine-Alanine repeat protects the fusion protein from proteasomal degradation and 
prevents subsequent presentation of potentially immunogenic peptides on MHC class I 
molecules (Levitskaya et al., 1997). This frustrates the induction of CTLs directed against the 
transgene product and conceals it from CTL-mediated immune attack. 
Another possibility to facilitate immune-evasion, which is feasible for small antiviral 
peptides only, is the generation of peptides which are devoid of MHC class I epitopes. Our 
group recently developed antiviral C peptides with potentially reduced immunogenicity, by 
mutating in silico-predicted immunodominant CTL epitopes within the peptide sequence. 
The mutated peptides retained excellent anti-HIV activity, while no immune responses 
could be detected in ELIspot assays (unpublished data). 
3.6 The target cell for intracellular immunization strategies 
Target cells for intracellular immunization are usually cells that can become infected with 
HIV-1 (mainly CD4+ T cells) or their progenitors (hematopoietic stem cells). For gene 
therapeutic approaches based on secreted antiviral molecules, the modification of non-HIV-
target cells is also feasible. So far, mature T cells and hematopoietic stem cells have been 
used in clinical trials. Advantages and disadvantages of both cell types are summarized in 
Table 1. Both have in common that they are relatively easy to obtain, and there are protocols 
for efficient ex vivo cultivation and transduction available. Gene modification of HSC has 
greater therapeutic potential, as it could restore a normal T cell repertoire, allow 
regeneration of HIV-specific T-helper cells and also protect monocytes/macrophages. 
However, current stem-cell based therapies are associated with greater risks and toxicity. 
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Target cell T cell HSC 
Easy to obtain ++ + 
Conditioning required - + 
Cell dose >1010 108-109 
Regeneration of T cell repertoire - + 
Protection of all HIV-1 target cells - + 
Insertional mutagenesis Limited + 
Table 1. The target cell: T cells versus hematopoietic stem cells (HSC). 
4. Vector systems for gene transfer 
The choice of the vector system may have a major impact on the efficacy of HIV-1 gene 
therapy approaches. There is no ideal vector suitable for all purposes, but the pros and cons 
have to be balanced for each application. Table 2 summarizes advantages and disadvantages 
of several vector systems commonly used for gene transfer. 
 
Vector type Application Titer 
Packaging 
capacity 
Inte-
gration
Immuno-
genicity 
Clinical 
trials 
Adenoviral 
ex vivo + in 
vivo 
1013 VP/ml up to 36 kb - ++ + 
AAV in vivo 1013 VP/ml 3-5 kb 
only 
with 
Rep 
+ + 
Gamma-
retroviral 
ex vivo 105-107 TU/ml 8-10 kb + - + 
Lentiviral ex vivo 
107 TU/ml 
(109-1010 
TU/ml)* 
up to 10 kb + - + 
SV-40 ex vivo 1012 VP/ml up to 5 kb + - - 
Foamyviral ex vivo 
105-106 TU/ml
(107 TU/ml)* 
>9 kb + - - 
Table 2. Vector systems for gene transfer in HIV-1 gene therapy. 
AAV, Adeno-Associated Virus; kb, kilo bases; SV-40, Simian Virus-40; TU, transducing 
units; VP, vector particles; * after concentration. 
Basic questions to be asked are, whether ex vivo or in vivo gene transfer is preferred and if 
long-term expression of the gene product is required. To our knowledge, a vector system 
that allows efficient direct in vivo gene transfer specifically into CD4+ T cells or HSC has not 
been developed so far. Therefore, approaches based on modification of these cell types 
(arming of T cells with TCRs or CARs, most intracellular immunizations) always rely on ex 
vivo gene transfer. In contrast, genes encoding secreted antiviral molecules may also be 
delivered to distinct production sites (e.g. liver, muscle) directly in vivo using adenovirus 
(Ad) or adeno-associated virus (AAV)-derived vectors. The second basic question deals with 
the long-term-expression of the transferred antiviral gene. Strategies involving arming of T 
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cells with antigen-specific receptors and intracellular immunization require stable and long-
lasting production of the antiviral molecules in proliferating cells (T cells or HSC). 
Consequently, for such approaches, integrating vectors are favorable. These include SV-40 
vectors and vectors derived from retroviruses. Stable expression of secreted gene products 
from slowly dividing cells like liver or muscle cells may also be achieved using non-
integrating vectors like adenoviral or AAV vectors. 
4.1 Non-integrating viral vectors 
The only vectors systems that currently allow direct in vivo gene transfer are non-integrating 
viral vectors. As their genome is not stably incorporated into the host cell chromosomes, 
these vectors have an improved safety profile compared to integrating vectors. For a direct 
in vivo application of integrating vectors, efficient systems for targeted vector delivery 
would be required, which are not yet available for use in man. Despite the lack of 
integration, non-integrating vector systems still allow sustained long-term transgene 
expression, if cells or tissues with a slow turnover are targeted, where the vector genome 
can stably persist. Moreover, non-integrating vectors can also be used to deliver zinc finger 
nucleases, which require only transient expression, to diving cells. A number of non-
integrating viral vectors have been evaluated for gene transfer. Currently, adenoviral 
vectors and vectors derived from the adeno-associated virus are in the focus of interest. 
Accordingly, Ad vectors are currently used in the above mentioned clinical trials to deliver 
CCR5-specific zinc finger nucleases to T cells ex vivo. 
Recombinant adenoviral vectors have been utilized as a gene transfer and vaccine 
platform for a long time. Ad vectors provide a huge packaging capacity (36 kb), allowing 
the transfer also of multiple therapeutic genes. Moreover, high-titer production is 
possible, facilitating direct in vivo application with high transduction efficacies. The major 
obstacle of adenoviral vectors is pre-existing immunity in the general human population. 
Vector-mediated immune responses cause rapid clearance of Ad vectors, moreover, 
severe side effects have been observed. This can be partly overcome by using engineered 
adenovirus serotypes (Dharmapuri et al., 2009). Moreover, production of Ad vectors is 
prone to contamination with replication competent adenovirus, which complicates clinical 
grade vector production. 
AAV is a non-pathogenic virus that belongs to the family of Parvoviridae. AAV-derived 
vectors have recently gained particular interest as gene transfer vehicles due to their 
apathogenicity and very low immunogenicity. Moreover, they can be used for direct in vivo 
gene delivery to both dividing and non-dividing cells. AAV can infect a variety of cell types 
in vivo and different serotypes of AAV have been shown to have varying preferences in their 
target cell type of choice (Chao et al., 2000; Halbert et al., 2000). However, AAV variants 
with a preference for T cells or hematopoietic stem cells have not been described. In the 
absence of the viral Rep protein, AAV vectors do not integrate into the host cell genome, but 
are maintained in episomal form in the nucleus. This allows very stable transgene 
expression without causing genotoxicity. The major disadvantage of AAV vectors is their 
small packaging capacity. In addition, vector production used to be laborious in the past 
and large-scale manufacturing for clinical trials was complicated. However, novel 
production systems facilitate faster and simpler high-titer production of AAV vectors in 
scaleable processes (Clement et al., 2009; Lock et al., 2010). 
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4.2 Integrating viral vectors 
Vectors derived from gamma-retroviruses (mostly murine leukaemia virus) and lentiviruses 
(HIV-1) have been used in numerous clinical trials, including ex vivo gene transfer trials for 
HIV-1 infection (DiGiusto et al., 2010; van Lunzen et al., 2007). Replication incompetent viral 
vectors are made from these viruses by deletion of all genes encoding enzymes and 
structural proteins (Gag, Pol, Env) from the viral genome. These genes have to be added in 
trans to produce infectious, but replication incompetent, vector particles. The tropism of the 
vector particles can be altered by modification of the envelope glycoprotein or by 
pseudotyping with the envelope protein from a different virus (Frecha et al., 2008; Funke et 
al., 2008). A major difference between gamma-retroviral and lentiviral vectors is that 
lentiviruses can infect dividing as well as non-dividing cells. In contrast, gamma-
retroviruses can only transduce dividing cells, as they rely on the collapse of the nuclear 
membrane during mitosis to enter the nucleus (Roe et al., 1993). Lentiviral transduction 
protocols therefore usually require a shorter period of pre-activation of the cells. As 
prolonged in vitro culture is associated with differentiation and a loss of in vivo repopulation 
potential, especially for HSC, lentiviral vectors have an advantage here. However, large-
scale production of lentiviral vectors is more difficult than gamma-retroviral vector 
production due to a lack of stable packaging cell lines. 
Both, gamma-retroviral and lentiviral vectors integrate randomly into the host cell genome. 
While gamma-retroviruses usually integrate near transcriptional start sites, lentiviruses 
have a preference for transcribed regions (Mitchell et al., 2004). As a consequence, 
transduction with these vectors is always associated with a risk of transformation due to 
insertional mutagenesis. Indeed, severe side effects caused by vector integration have been 
reported in gene therapy clinical trials (Hacein-Bey-Abina et al., 2008; Howe et al., 2008). 
Experiments in animal models showed that vector genotoxicity is higher for transduction of 
hematopoietic stem cells than for mature T cells (Newrzela et al., 2008) and lower for self 
inactivating (SIN) vectors compared to conventional long terminal repeat (LTR)-driven 
vectors (Modlich et al., 2009). SIN vectors have deletions in the promotor and enhancer 
elements of the 3’LTR, thereby reducing the genotoxic risks, as transactivation of 
neighboring protooncogenes is less likely. In these vectors, expression of the transgene 
cassette is driven from an internal promoter. 
Foamyviruses also belong to the family of retroviruses. Foamyviral vectors are generated by 
deleting enzymes and structural genes from the viral genome and adding these in trans 
during vector production (Rethwilm, 2007). Foamyvirus-derived vectors efficiently 
transduce resting cells, which makes them an ideal tool to transduce hematopoietic stem 
cells ex vivo (Hirata et al., 1996; Leurs et al., 2003). However, just like SV-40 vectors, 
foamyviral vectors have not yet been tested in clinical trials.  
Simian virus-40 (SV-40) belongs to the family of Polyomaviridae. It has been one of the first 
viruses used as a gene transfer vehicle (Gething & Sambrook, 1981). For the construction of 
gene transfer vectors, all coding sequences except the origin of replication and the 
packaging signal can be deleted from wild type SV-40 (Strayer et al., 2002). The resulting 
vectors efficiently transduce hematopoietic stem cells and lymphocytes in vitro, but have 
never been tested in clinical trials (Strayer et al., 2005). 
4.3 Targeted integration 
Past clinical trials have shown that random integration of a transgene delivered by an 
integrating vector bears the risk of severe side effects due to insertional mutagenesis. 
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Targeted integration of transgenes into the host cell genome is therefore expected to 
massively increase safety. The CCR5 locus is considered to be a safe harbor for transgene 
integration, as a naturally occurring deletion of 32 bp in the coding sequence for CCR5 
causes no clinical symptoms. Moreover, this deletion is associated with a reduced 
susceptibility for HIV-1 infection (Huang et al., 1996; Samson et al., 1996). Therefore, 
targeted integration of an anti-HIV transgene into the CCR5 locus could even provide an 
additional antiviral effect, due to disruption of the CCR5 gene. Zinc finger nucleases binding 
to CCR5 have been used in vitro and in animal models to destroy the CCR5 locus, rendering 
the treated cells resistant to HIV-1 infection (Holt et al., 2010; Perez et al., 2008). A 
combination of this approach with targeted integration of antiviral genes holds especially 
great promise. For such a strategy a donor DNA encoding the desired antiviral gene and 
containing sequences homologous to the target site has to be present in the cells during the 
repair of ZFN-induced double-strand breaks by cellular enzymes. This results in the 
incorporation of the foreign DNA into the targeted region of the host genome by non-
homologous end joining mediated by the cellular DNA repair machinery (Cathomen & 
Joung, 2008). Such approaches require only transient expression of the zinc finger nuclease 
and the transgene to achieve stable integration into the host cell genome, which allows use 
of non-integrating vector systems for gene transfer. 
As an alternative to zinc finger nucleases, AAV vectors that contain the viral Rep protein in 
cis or in trans can also be used for targeted integration, as in the presence of Rep, AAV 
vectors target their genome preferentially to a locus on the human chromosome 19, termed 
AAVS1, without causing any apparent adverse effects (Surosky et al., 1997). As the CCR5 
locus, AAVS1 is thus considered a safe harbor for vector integration. 
5. Conclusions 
Gene therapeutic approaches for the treatment and possibly prevention of HIV-1 infection 
hold considerable promise. Although the final breakthrough has not yet been achieved in 
clinical trials, there has been substantial progress over the last years and future 
developments might leverage this technology. The major reason for the limited efficacy seen 
in all HIV-1 gene therapy clinical trials up to now has been the insufficient level of gene 
modification. It will therefore be particularly important to develop optimized therapeutic 
regimen and gene transfer technologies that allow therapeutically effective engraftment 
levels of functional, gene modified cells. Efficient protection of CD4+ T cells could possibly 
be achieved by using a combination of antiviral genes targeting different steps of the viral 
life cycle, conferring a substantial in vivo selective survival advantage and ideally also a 
therapeutic bystander effect on unmodified cells. This review describes the potent gene 
therapeutic tools that have been developed in the past years and it will be exciting to see if 
these can be integrated into an effective treatment regimen in the near future. 
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